Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Equity Average (2021 - 2025)

Historic Equity Average for TScan Therapeutics (TCRX) over the last 5 years, with Q3 2025 value amounting to $160.4 million.

  • TScan Therapeutics' Equity Average fell 3377.46% to $160.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.4 million, marking a year-over-year decrease of 3377.46%. This contributed to the annual value of $195.9 million for FY2024, which is 5654.63% up from last year.
  • As of Q3 2025, TScan Therapeutics' Equity Average stood at $160.4 million, which was down 3377.46% from $193.5 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Equity Average high stood at $242.2 million for Q3 2024, and its period low was -$55.0 million during Q2 2021.
  • For the 5-year period, TScan Therapeutics' Equity Average averaged around $136.5 million, with its median value being $153.2 million (2022).
  • Its Equity Average has fluctuated over the past 5 years, first surged by 43173.71% in 2022, then crashed by 4209.85% in 2023.
  • TScan Therapeutics' Equity Average (Quarter) stood at $167.4 million in 2021, then tumbled by 35.47% to $108.0 million in 2022, then skyrocketed by 48.01% to $159.9 million in 2023, then skyrocketed by 46.97% to $235.0 million in 2024, then crashed by 31.77% to $160.4 million in 2025.
  • Its last three reported values are $160.4 million in Q3 2025, $193.5 million for Q2 2025, and $225.6 million during Q1 2025.